Mineralys Therapeutics Presents Phase 2 Explore-CKD Trial Of Lorundrostat At ASN Kidney Week 2025
Benzinga Newsdesk 1 year ago
BiotechNewsEventsGeneral
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN Trial of lorundrostat to
- ~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~
- ~ Phase 3 data of the Launch-HTN Trial of lorundrostat to be included in "Best of Journal of the American Medical Association and the New England Journal of Medicine" presentation~